Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with most benefits holding after adjusting…
Innogen has licensed its China-approved GLP-1 efsubaglutide alfa to Arcera for Africa, Eastern Europe, Latin America and the Middle East in a deal worth over $1 billion.
A Science review weighs whether Ozempic, Wegovy and Mounjaro protect the brain. Observational data look promising, but Alzheimer trials were negative. What we know.
Real-world data on 5,872 Ro patients show the once-daily Wegovy pill delivered 6.2% average weight loss in three months, slightly above trial results.
China approved Eli Lilly's orforglipron (Muyouda), its first GLP-1 weight-loss pill. Trial data, rivals, market outlook and what remains unknown.
Aspen Pharmacare won approval for generic semaglutide in Brazil and South Africa, with launches due within months and first batches made in India. What it means for prices.
Survodutide weight loss reached up to 13.1% versus 3.1% on placebo at 76 weeks in the Phase III SYNCHRONIZE-2 trial in people with type 2 diabetes.
Trevogrumab added to semaglutide cut lean muscle loss in Regeneron's nearly 1,000-patient trial, preserving over 70% of thigh muscle at 52 weeks.